A 31-amino-acid GLP-1 analog engineered for once-weekly dosing. FDA-approved for Type 2 diabetes and obesity. Achieves 15-17% body weight loss — the most effective anti-obesity peptide drug on the market.
Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), an incretin hormone naturally secreted by intestinal L-cells after eating. It is 94% structurally similar to native human GLP-1 but has been engineered with three key modifications that extend its half-life from 2 minutes to approximately 7 days.
Marketed as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral diabetes), semaglutide has become the most commercially successful peptide drug in history. In the STEP clinical trial program, patients lost an average of 15-17% of their body weight — results previously achievable only through bariatric surgery.
The sequence contains a high proportion of charged and polar residues, making native GLP-1 highly hydrophilic — which contributes to its rapid renal clearance (and 2-minute half-life). The C18 fatty acid conjugation at Lys26 fundamentally changes the pharmacokinetics by enabling albumin binding.
Semaglutide binds to and activates the GLP-1 receptor, a G protein-coupled receptor (GPCR) expressed in the pancreas, GI tract, heart, kidneys, and brain. Activation triggers adenylyl cyclase → cAMP → PKA signaling, with different downstream effects depending on the tissue.
In the pancreas, it enhances glucose-dependent insulin secretion from β-cells and suppresses glucagon from α-cells. In the brain, it crosses the blood-brain barrier and activates satiety neurons (POMC/CART) while inhibiting hunger neurons (NPY/AgRP) in the arcuate nucleus of the hypothalamus. In the stomach, it slows gastric emptying, prolonging the feeling of fullness after meals.
The three structural modifications that make semaglutide clinically viable are: (1) Aib at position 8 — α-aminoisobutyric acid replaces alanine, creating steric hindrance that blocks DPP-4 from cleaving the peptide at its primary degradation site; (2) Arg34 replacing Lys34, preventing fatty acid attachment at the wrong position; (3) C18 fatty diacid at Lys26 via a mini-PEG linker, enabling non-covalent binding to serum albumin (half-life ~19 days), which shields semaglutide from renal clearance and proteolysis.
| Pathway | Effect | Significance |
|---|---|---|
| POMC/CART activation | Stimulates anorexigenic neurons in hypothalamus | Reduces appetite and food intake |
| NPY/AgRP inhibition | Suppresses orexigenic neurons | Decreases hunger drive |
| Delayed gastric emptying | Slows food transit from stomach | Prolongs satiety, reduces glucose spikes |
| WAT→BAT browning | May promote white-to-brown fat conversion via FNDC5/irisin | Increases energy expenditure |
| Cardiovascular protection | Reduces atherosclerosis progression, inflammation | 20% reduction in MACE events (SELECT trial) |
Semaglutide has the most robust clinical evidence of any therapeutic peptide, with multiple large Phase III randomized controlled trials.
| Study Area | Design | Key Findings | Evidence |
|---|---|---|---|
| SUSTAIN trials | Phase III RCTs, T2D, n=8,000+ | Superior HbA1c reduction vs comparators; dose-dependent weight loss | Level I |
| STEP 1-5 | Phase III RCTs, obesity, n=4,500+ | 15-17% mean weight loss from baseline at 68 weeks; 30%+ of patients lost ≥20% | Level I |
| SELECT | Phase III RCT, CV outcomes, n=17,604 | 20% reduction in major adverse cardiovascular events vs placebo | Level I |
| PIONEER | Phase III, oral semaglutide | Oral 14mg daily showed significant HbA1c and weight reduction; GI side effects common | Level I |
| OASIS 1 | Phase III, oral high-dose obesity | Oral 50mg showed ~16% weight loss — comparable to injectable | Level I |
Weight regain after discontinuation is significant. In the STEP 1 extension study, participants regained approximately two-thirds of lost weight within one year of stopping semaglutide. This suggests semaglutide treats obesity as a chronic condition requiring ongoing medication, similar to how statins manage cholesterol.
GI side effects: Nausea (40-44%), vomiting, diarrhea, and constipation are the most common adverse effects. Typically mild-to-moderate and improve with dose escalation over 4-8 weeks.
Thyroid cancer (boxed warning): GLP-1 agonists caused thyroid C-cell tumors in rodents. No increased risk confirmed in humans, but semaglutide is contraindicated in patients with personal/family history of medullary thyroid carcinoma (MTC) or MEN2.
Pancreatitis: Rare cases of acute pancreatitis reported. Patients should seek immediate care for severe persistent abdominal pain.
Gallbladder disease: Increased risk of cholelithiasis (gallstones) associated with rapid weight loss.
Muscle mass loss: 15-40% of weight lost may be lean mass. Resistance training and adequate protein intake are recommended during treatment.
| Jurisdiction | Status |
|---|---|
| FDA | Approved: Ozempic (T2D, 2017), Wegovy (obesity, 2021), Rybelsus (oral T2D, 2019/2025) |
| EMA | Approved for T2D and weight management |
| WADA | Not banned (legitimate medication) |
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Class | GLP-1 receptor agonist | Dual GLP-1/GIP receptor agonist |
| Size | 31 amino acids | 39 amino acids |
| Weight loss | 15-17% (STEP trials) | 20-22% (SURMOUNT trials) |
| Mechanism | GLP-1 receptor only | Both GLP-1 and GIP receptors |
| Dosing | Once weekly SC | Once weekly SC |
| Brand names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| Manufacturer | Novo Nordisk | Eli Lilly |